Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

bafetinib (INNO-406)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

LadRx

Drug class:

Bcr-abl tyrosine kinase inhibitor

Related drugs:

FGF4 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	FGF4 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	INNO-406 Sensitive: D – Preclinical INNO-406 Sensitive : D	INNO-406 Sensitive: D – Preclinical INNO-406 Sensitive : D
FGF3 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	FGF3 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	INNO-406 Sensitive: D – Preclinical INNO-406 Sensitive : D	INNO-406 Sensitive: D – Preclinical INNO-406 Sensitive : D
FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	INNO-406 Sensitive: D – Preclinical INNO-406 Sensitive : D	INNO-406 Sensitive: D – Preclinical INNO-406 Sensitive : D